Company intelligence / Profile preview
QLSF Biotherapeutics
South San Francisco, California, United Statesqlsfbio.com ↗
- Ownership
- Private
- Employees
- ~16
- Development stage
- Other
01
Overview
QLSF Biotherapeutics has multiple programs in clinical development, with their most advanced asset QL-301 (PD-L1 x 4-1BB) in Phase 2 for solid tumors. Several other bispecific antibodies are in Phase 1 trials.
- Therapeutic areas
- OncologyHematology
- Modalities
- Antibody-based therapeuticsBispecific antibodiesT cell engagersFusion proteins
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
Qilu Pharmaceutical
Beyond the preview
Go deeper on QLSF Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QLSF Biotherapeutics.